Blog

Blog

T-Cell Dysfunction and Cancer Therapy

T Cell-Based Assay Services Looking for T cell-based assay development? Want a GMP-compliant T cell-based assay? Need to develop a custom T cell-based potency assay? Need an IND/BLA-ready T cell-based assay? Learn more about our T cell-based assay services → Introduction T-cell dysfunction is a major barrier to effective and durable immunity […]

Recent Articles

Advanced Molecular Insights into T-Cell Dysfunction and Therapy

Blog

T-Cell Dysfunction and Cancer Therapy

T Cell-Based Assay Services Looking for T cell-based assay development? Want a GMP-compliant T cell-based assay? Need to develop a custom T cell-based potency assay? Need an IND/BLA-ready

A New Era in Cancer Treatment: Personalized mRNA Vaccines Show Phase III Success

Blog

Can Vaccines Treat Cancer? A Landmark Melanoma Trial Offers New Hope

Cell-Based Assay Services Looking for cell-based assay development? Want a GMP-compliant cell-based assay? Need to develop a custom cell-based potency assay? Need an IND/BLA-ready cell-based assay? Learn more about

All Blogs

Transforming Peptides into Therapeutic Drugs

Peptide drugs are synthetic short chains of amino acids that mimic natural hormones to manage complex metabolic, endocrine, and oncological conditions. Peptide drugs target receptors with high specificity, therefor

All Blogs

A New Therapeutic Target for MASH: The GPNMB–RYK Signaling Axis Opens New Opportunities

Metabolic-dysfunctional Associated SteatoHepatitis (MASH) is rising globally but effective treatment is limited. It is characterized by inflammation and variable fibrosis, which can progress to cirrhosis and hepatocellular carcinoma.

Bispecific Antibodies: From Cancer Immunotherapy to Next-Generation Precision Medicine

Blog

Bispecific Antibodies: How Dual-Targeting Therapies Are Transforming Modern Medicine

Bispecific antibody therapy uses engineered antibodies designed to bind two different targets simultaneously. This dual-targeting ability opens up treatment strategies that arenot possible with regular monoclonal antibodies. How

Four stages of tumor drug resistance: a genetically heterogeneous tumor before treatment, drugs killing sensitive cells, resistant clones surviving and expanding, and relapse as a resistant tumor

All Blogs

Genetic Evolution of Tumor Cells as a Major Driver of Resistance to Anticancer Drugs

The remarkable clinical success of targeted therapies, immunotherapies, antibody-drug conjugates (ADCs), and targeted protein degraders (TPDs) has substantially improved outcomes for many cancer patients. Nevertheless, durable therapeutic responses remain

All Blogs

Exponential Progression of Targeted Protein Degradation Drug Discovery

INTRODUCTION Targeted protein degradation (TPD) has emerged as a transformative therapeutic modality in modern drug discovery. Unlike conventional small-molecule inhibitors, which typically suppress protein function through occupancy-driven mechanisms,

All Blogs

Tumor Intrinsic Resistance Mechanisms to CAR T-cells

Introduction Chimeric antigen receptor (CAR) T-cell therapy has demonstrated unprecedented clinical efficacy in the treatment of hematologic malignancies; however, primary resistance and disease relapse remain significant barriers to durable

All Blogs

Can AI Enhanced SAR Overcome T Cell Dysfunction

T-cell dysfunction is a major obstacle to effective immunotherapy in cancer, chronic infection, and autoimmune disease, where persistent antigen exposure and immunosuppressive signaling lead to impaired proliferation, reduced effector

All Blogs

Cytokine “Armored” CAR-T Cells: Engineering the Next Generation of Cellular Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for hematologic malignancies, yet its efficacy in solid tumors remains limited by poor persistence, T-cell exhaustion, and an immunosuppressive tumor